Omeros Corporation (OMER) Given “Buy” Rating at Maxim Group
Omeros Corporation (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by investment analysts at Maxim Group in a report released on Tuesday. They presently have a $19.00 price objective on the biopharmaceutical company’s stock. Maxim Group’s price target would indicate a potential upside of 150.00% from the company’s previous close.
Several other research analysts have also commented on OMER. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price objective on shares of Omeros Corporation in a research report on Monday. WBB Securities reissued a “buy” rating and issued a $75.00 price objective on shares of Omeros Corporation in a research report on Monday. S&P Equity Research raised their price objective on Omeros Corporation from $7.65 to $8.63 in a research report on Monday. Zacks Investment Research lowered Omeros Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, October 12th. Finally, Wedbush reissued an “outperform” rating and issued a $56.00 price objective (down from $62.00) on shares of Omeros Corporation in a research report on Thursday, August 11th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Omeros Corporation currently has an average rating of “Buy” and an average price target of $32.45.
Shares of Omeros Corporation (NASDAQ:OMER) traded down 0.1303% during midday trading on Tuesday, reaching $7.5901. The company’s stock had a trading volume of 527,130 shares. The company’s market cap is $298.24 million. The stock’s 50-day moving average price is $10.51 and its 200-day moving average price is $11.63. Omeros Corporation has a 12-month low of $7.20 and a 12-month high of $16.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/omeros-corporation-omer-given-buy-rating-at-maxim-group.html
Omeros Corporation (NASDAQ:OMER) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.18. The firm earned $10 million during the quarter, compared to analyst estimates of $9.80 million. During the same quarter in the previous year, the business posted ($0.44) EPS. Omeros Corporation’s revenue was up 212.5% compared to the same quarter last year. On average, analysts expect that Omeros Corporation will post ($1.55) EPS for the current fiscal year.
In related news, VP Marcia S. Kelbon sold 16,000 shares of the business’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the sale, the vice president now directly owns 179,597 shares of the company’s stock, valued at $1,959,403.27. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Marcia S. Kelbon sold 15,900 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $11.56, for a total value of $183,804.00. Following the completion of the sale, the vice president now directly owns 179,497 shares of the company’s stock, valued at $2,074,985.32. The disclosure for this sale can be found here. Insiders own 13.60% of the company’s stock.
A number of hedge funds have recently made changes to their positions in OMER. Sheaff Brock Investment Advisors LLC purchased a new stake in shares of Omeros Corporation during the second quarter valued at $105,000. Bourgeon Capital Management LLC purchased a new stake in shares of Omeros Corporation during the second quarter valued at $158,000. BlackRock Advisors LLC raised its stake in shares of Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares in the last quarter. Mesirow Financial Investment Management Equity Management purchased a new stake in shares of Omeros Corporation during the second quarter valued at $244,000. Finally, Gradient Investments LLC raised its stake in shares of Omeros Corporation by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 814 shares in the last quarter. 48.04% of the stock is owned by hedge funds and other institutional investors.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.